Presence of coronary artery calcium and risk of incident ASCVD events increased with increasing SBP levels in individuals with a SBP between 90 and 129 mmHg and no other traditional ASCVD risk factors.
This post-hoc analysis demonstrated similar BP reductions after renal denervation (RDN) across high-risk subgroups and ASCVD risk scores. Reductions were sustained up to 3 years after RDN.
In a case-control study of Chinese adults divided in age groups, earlier onset of hypertension was associated with higher risk of all-cause mortality and a trend for higher risk of CVD.
Reduction of antihypertensive medication in patients ≥80 years who were on ≥2 antihypertensive medication was noninferior to usual care with regard to SBP control at 12 weeks.
Recently, three papers were published in the N Engl J Med on the effect of ACE inhibitors and ARBs in patients with COVID-19. All three studies showed no evidence that ACE inhibitors or ARBs affect the risk of COVID-19.
A randomized, phase 3 trial, called DARE-19, evaluates the effect of dapagliflozin on disease progression, clinical complications and mortality in patients hospitalized with COVID-19, who also have CV, metabolic or kidney risk factor.
This presentation is part of a webinar on COVID-19, ACE2 and RAAS inhibition and focusses on scientific data that is available on the ACE2 receptor and RAAS inhibitors.
As part of a webinar on COVID-19, ACE2 and RAASi, prof. Epstein presents clinical implications of discontinuation of RAASi in COVID-19 patients and strongly recommends to continue use of these medications.
ACC 2020 The SPYRAL HTN-OFF MED Pivotal Trial showed that renal denervation lowers 24h SBP and office SBP compared to sham control in hypertensive patients in absence of medications.
Following the ESC statement, a joint statement of the HFSA, ACC and AHA has now been published on continued use of RAASi during the COVID-19 pandemic.
The ESC Council on Hypertension has released a statement, strongly recommending to continue treatment of ACEi and ARBs in times of the COVID-19 pandemic, as evidence for harmful effects of these drugs in context of COVID-19 is lacking.
A community-based multicomponent intervention led to a greater reduction in BP than usual care among adults with hypertension in rural communities in three South Asian countries.